News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promedior Announces Presentation of Preclinical Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage



5/7/2012 9:53:44 AM

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that data from preclinical studies of Pentraxin-2 (PTX-2) were presented yesterday at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. In a poster entitled “Recombinant Pentraxin-2 (rPTX-2) Shifts Macrophage Phenotype, Suppresses Subretinal NV, and Reduces Associated Vascular Leakage and Collagen Deposition”, Promedior and collaborators from The Johns Hopkins University Wilmer Eye Institute highlighted the efficacy and utility of Pentraxin-2 in suppressing fibrosis, neovascularization and vascular leak in independent models of age-related macular degeneration (AMD) and diabetic retinopathy.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES